Sorry, there was a problem.

An unexpected error occurred and your request couldn't be handled. Please call a Dignity Health representative at
(844) 274-8497
OR
Chat with us here.

Reference code:

Clinical Trials


The University of Arizona Cancer Center at Dignity Health St. Joseph’s Hospital and Medical Center leads several clinic trials within our Phoenix cancer center.

Below is a list of our active trials. Select the study name for specific information about that trial. For more information about how to participate in any of the clinical trials listed below, contact Mindy Bowers at 855.622.6845.

BASAL CELL CARCINOMA (SKIN CANCER) 

Panayiotis Savvides, MD

PHXE-17-0101-80-15

A Phase 2 Study of REGN2810, A Fully Human Monoclonal Antibody to Programmed Death-1, in Patients with Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or were Intolerant of Prior Hedgehog 

BLADDER CANCER

Jue Wang, MD

PHX-15-0014-10-15

A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer (S1314)

Jue Wang, MD


PHXE-16-0204-80-15

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

BREAST CANCER

Albert Wendt, MD

PHX-15-0013-10-15

S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer.

Albert Wendt, MD

PHXE-16-0167-10-15

EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

CANCER PREVENTION

Linda Garland, MD

1403269898

Clinical study of the effect of combined treatment of aspirin and zileuton on biomarkers of tobacco-related carcinogenesis in current smokers

Nathalie Zeitouni, MD

PHXB-16-0142-80-15

Cyclic PDT for the Prevention of Actinic Keratosis and Non Melanoma Skin Cancer in Solid Organ Transplant Recipients

CERVICAL CANCER

John Farley, MD

PHXA-16-0094-80-15

PHASE 3 STUDY OF ADXS11-001 ADMINISTERED FOLLOWING CHEMORADIATION AS ADJUVANT TREATMENT FOR HIGH RISK LOCALLY ADVANCED CERVICAL CANCER:AIM2CERV

CUTANEOUS SQUAMOUS CELL CANCER

Panayiotis Savvides, MD

PHXE-16-0205-80-15

A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH - 1 (PD-1), IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA

CUTANEOUS T CELL LYMPHOMA

Nathalie Zeitouni, MD

PHXE-17-0117-80-15

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma

ENDOMETRIAL CANCER

John Farley, MD

PHX-15-0022-10-15

A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer

HEAD AND NECK CANCER

Panayiotis Savvides, MD

PHXE-15-0031-10-15

A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer

Panayiotis Savvides, MD

PHXB-16-0155-10-15

A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

KIDNEY CANCER

Jue Wang, MD

PHXE-17-0114-10-15

A Phase 3 RandOmized Study Comparing PERioperative Nivolumab Vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

LIVER CANCER

Nitika Thawani, MD

PHX-13RT127

RANDOMIZED PHASE III STUDY OF SORAFENIB VERSUS STEREOTACTIC BODY RADIATION THERAPY FOLLOWED BY SORAFENIB IN HEPATOCELLULAR CARCINOMA

LUNG CANCER

Panayiotis Savvides, MD

PHX-15-0011-80-15

SHERLOC: A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

MALIGNANT BOWEL OBSTRUCTION

David Row, MD

PHXB-17-0120-10-15

PROSPECTIVE COMPARATIVE EFFECTIVENESS TRIAL FOR MALIGNANT BOWEL OBSTRUCTION

OVARIAN CANCER

John Farley, MD

PHX-15-0002-10-15

Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? (GOG-0225)

John Farley, MD

PHXE-16-0001-80-15

FORWARD 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator’s Choice of Chemotherapy in Women with Folate Receptor α−positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer

John Farley, MD

PHXA-16-0174-80-15

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer

PRECISION MEDICINE & RARE CANCERS

Jue Wang, MD

PHXE-17-0216-10-15

EAY131: Molecular Analysis for Therapy Choice (MATCH)

Jue Wang, MD

PHXE-17-0349-10-15

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

PROSTATE CANCER

Shyamal Patel, MD

PHX-11RT007

Androgen Deprivation Therapy and high Dose Radiation With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer

Jue Wang, MD

PHXB-15-0015-80-15

A Prospective Observational Cohort Study of Patients with Castration-Resistant Prostate Cancer (CRPC) in the United States